Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -31.99% is 55% above its 5-year average of -71.17%, near the high end of its 5-year range (-443.10%–-27.92%).
As of the fiscal period ended Tuesday, June 30, 2026. 57.51% above its 12-month average of -75.29%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -31.99%.
RETURN ON EQUITY (ROE)
-31.99%
RETURN ON EQUITY (ROE) AVG TTM
-75.29%
RETURN ON EQUITY (ROE) AVG 3Y
-68.59%
RETURN ON EQUITY (ROE) AVG 5Y
-71.17%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+57.51%
CURRENT VS 3Y AVG
+53.36%
CURRENT VS 5Y AVG
+55.05%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-33.06%
median of 381 covered companies
CURRENT VS SECTOR MEDIAN
+3.23%
vs the sector median at left
Aprea Therapeutics, Inc.
Market Cap
$8.37M
Return on Equity (ROE)
-31.99%
TTM Avg
-75.29%
3Y Avg
-68.59%
5Y Avg
-71.17%
Market Cap
$8.76M
Return on Equity (ROE)
-7.36%
TTM Avg
-85.10%
3Y Avg
-73.72%
5Y Avg
-96.61%
Market Cap
$7.77M
Return on Equity (ROE)
-618.74%
TTM Avg
149.09%
3Y Avg
4.64%
5Y Avg
-24.92%
Market Cap
$7.75M
Return on Equity (ROE)
-91.75%
TTM Avg
-295.51%
3Y Avg
-88.38%
5Y Avg
-106.70%
Market Cap
$9.09M
Return on Equity (ROE)
-34.67%
TTM Avg
10.89%
3Y Avg
102.13%
5Y Avg
71.00%
Market Cap
$9.42M
Return on Equity (ROE)
N/A
TTM Avg
-2138.11%
3Y Avg
-1780.63%
5Y Avg
-1152.40%
Market Cap
$7.03M
Return on Equity (ROE)
-218.65%
TTM Avg
-54.74%
3Y Avg
-35.36%
5Y Avg
-35.36%
Market Cap
$9.79M
Return on Equity (ROE)
-440.15%
TTM Avg
-145.56%
3Y Avg
-96.97%
5Y Avg
-42.16%
Market Cap
$6.88M
Return on Equity (ROE)
-370.16%
TTM Avg
-148.31%
3Y Avg
-87.53%
5Y Avg
-43.20%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aprea Therapeutics, Inc. (APRE) | $8.37M | -31.99% | -75.29% | -68.59% | -71.17% |
| Advanced Biomed Inc. Common Stock (ADVB)vs › | $8.76M | -7.36% | -85.10% | -73.72% | -96.61% |
| GT Biopharma, Inc. (GTBP)vs › | $7.77M | -618.74% | 149.09% | 4.64% | -24.92% |
| CNS Pharmaceuticals, Inc. (CNSP)vs › | $7.75M | -91.75% | -295.51% | -88.38% | -106.70% |
| Healthcare Triangle, Inc. (HCTI)vs › | $9.09M | -34.67% | 10.89% | 102.13% | 71.00% |
| HeartSciences Inc. (HSCS)vs › | $9.42M | N/A | -2138.11% | -1780.63% | -1152.40% |
| Curanex Pharmaceuticals Inc Common Stock (CURX)vs › | $7.03M | -218.65% | -54.74% | -35.36% | -35.36% |
| Ainos, Inc. (AIMD)vs › | $9.79M | -440.15% | -145.56% | -96.97% | -42.16% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -370.16% | -148.31% | -87.53% | -43.20% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -108.00% | -445.77% | -254.63% | -239.85% |
ROE
-32.0%
ROA
-29.1%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -31.99% |
| 2026-03-31 | -27.92% |
| 2025-12-31 | -101.27% |
| 2025-09-30 | -112.01% |
| 2025-06-30 | -103.25% |
| 2025-03-31 | -90.56% |
| 2024-12-31 | -67.12% |
| 2024-09-30 | -61.54% |
| 2024-06-30 | -48.11% |
| 2024-03-31 | -43.97% |
| 2023-12-31 | -78.22% |
| 2023-09-30 | -65.48% |
| 2023-06-30 | -60.23% |
| 2023-03-31 | -412.00% |
| 2022-12-31 | -439.34% |
| 2022-09-30 | -443.10% |
| 2022-03-31 | -81.20% |
| 2021-12-31 | -74.99% |
| 2021-09-30 | -83.80% |
| 2021-06-30 | -78.14% |
| 2021-03-31 | -77.73% |
| 2020-12-31 | -69.10% |
| 2020-09-30 | -57.47% |
| 2020-06-30 | -45.04% |
| 2020-03-31 | -29.98% |
| 2019-12-31 | -22.58% |
| 2019-06-30 | -29.39% |
